Importance of characterizing determinants of variability in exposure: Application to dasatinib in subjects with chronic myeloid leukemia

Journal of Clinical Pharmacology

Volumn 48, Issue 11, 2008, Pages 1254-1269

  Dai, Guowei ^a   Pfister, Marc ^a   Blackwood Chirchir, Anne ^a   Roy, Amit ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Absorption modeling; BCR ABL; Chronic myeloid leukemia; Dasatinib; Model based analysis; Modeling and simulation; SRC

Indexed keywords

ANTACID AGENT; CYTOCHROME P450 3A4; DASATINIB; ENZYME INDUCING AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; IMATINIB; OXIDOREDUCTASE INHIBITOR; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CHRONIC DRUG ADMINISTRATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EXPOSURE; HUMAN; INTERINDIVIDUAL VARIABILITY; INTEROCCASION VARIABILITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; VARIANCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; FEASIBILITY STUDIES; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES; YOUNG ADULT;

EID: 54049100461     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008320604     Document Type: Article

References (44)

1. Sheiner LB Learning versus confirming in clinical drug development. Clin Pharmacol Ther. 1997 ; 61: 275-291.
2. Bhattaram VA, Bonapace C., Chilukuri DM, et al. Impact of pharmacometric reviews on new drug approval and labeling decisions: a survey of 31 new drug applications submitted between 2005 and 2006. Clin Pharmacol Ther. 2007 ; 81: 213-221.
3. Lesko LJ Paving the critical path: how can clinical pharmacology help achieve the vision ? Clin Pharmacol Ther. 2007 ; 81: 170-177.
4. Barrett JS, Labbe L., Pfister M. Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy. Clin Pharmacokinet. 2005 ; 44: 591-625.
5. Friberg LE, Henningsson A., Maas H., Nguyen L., Karlsson MO Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol. 2002 ; 20: 4713-4721.
6. Latz JE, Rusthoven JJ, Karlsson MO, Ghosh A., Johnson RD Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol. 2006 ; 57: 427-435.
7. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol. 1996 ; 14: 2590-2611.
8. Miller AA, Tolley EA, Niell HB Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer. Clin Cancer Res. 1998 ; 4: 1705-1710.
9. Chatelut E., Canal P., Brunner V., et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst. 1995 ; 87: 573-580.
10. Reigner B., Blesch K., Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet. 2001 ; 40: 85-104.
11. Leger F., Loos WJ, Fourcade J., et al. Factors affecting pharmacokinetic variability of oral topotecan: a population analysis. Br J Cancer. 2004 ; 90: 343-347.
12. de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S., Beijnen JH Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review. Clin Pharmacokinet. 2005 ; 44: 147-173.
13. Talpaz M., Shah NP, Kantarjian H., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006 ; 354: 2531-2541.
14. Cortes J., Rousselot P., Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007 ; 109: 3207-3213.
15. Hochhaus A., Kantarjian HM, Baccarani M., et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007 ; 109: 2303-2309.
16. Guilhot F., Apperley J., Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007 ; 109: 4143-4150.
17. Quintas-Cardama A., Kantarjian H., Jones D., et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood. 2007 ; 109: 497-499.
18. Shah NP, Tran C., Lee FY, Chen P., Norris D., Sawyers CL Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004 ; 305: 399-401.
19. Tokarski JS, Newitt JA, Chang CY, et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 2006 ; 66: 5790-5797.
20. Lombardo LJ, Lee FY, Chen P., et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004 ; 47: 6658-6661.
21. Donato NJ, Wu JY, Stapley J., et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res. 2004 ; 64: 672-677.
22. Hare T., Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005 ; 65: 4500-4505.
23. SPRYCEL® (dasatinib) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company ; July 2006.
24. Pfister M., Martin NE, Haskell LP, Barrett JS Optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240. J Clin Pharmacol. 2004 ; 44: 621-631.
25. Higaki K., Yamashita S., Amidon GL Time-dependent oral absorption models. J Pharmacokinet Pharmacodyn. 2001 ; 28: 109-128.
26. Karlsson MO, Sheiner LB The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993 ; 21: 735-750.
27. Yano Y., Beal SL, Sheiner LB Evaluating pharmacokinetic/ pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn. 2001 ; 28: 171-192.
28. Food and Drug Administration (FDA). Guidance for Industry: Population Pharmacokinetics. Rockville, MD: Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), FDA ; 1999.
29. Ette EI, Williams PJ, Kim YH, Lane JR, Liu MJ, Capparelli EV Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol. 2003 ; 43: 610-623.
30. Roy A., Ette EI A pragmatic approach to the design of population pharmacokinetic studies. AAPS J. 2005 ; 7: E408 - E420.
31. Hossain M., Wright E., Baweja R., Ludden T., Miller R. Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and a controlled release (CR) dosage form of alprazolam. Pharm Res. 1997 ; 14: 309-315.
32. Hennig S., Wainwright CE, Bell SC, Miller H., Friberg LE, Charles BG Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. Clin Pharmacokinet. 2006 ; 45: 1099-1114.
33. Wade JR, Snoeck E., Duff F., Lamb M., Jorga K. Pharmacokinetics of ribavirin in patients with hepatitis C virus. Br J Clin Pharmacol. 2006 ; 62: 710-714.
34. Hennig S., Waterhouse TH, Bell SC, et al. A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. Br J Clin Pharmacol. 2007 ; 63: 438-450.
35. Othman AA, Tenero DM, Boyle DA, Eddington ND, Fossler MJ Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate. AAPS J. 2007 ; 9: E208 - E218.
36. Kappelhoff BS, Huitema AD, Yalvac Z., et al. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clin Pharmacokinet. 2005 ; 44: 849-861.
37. Kappelhoff BS, Huitema AD, Crommentuyn KM, et al. Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients. Br J Clin Pharmacol. 2005 ; 59: 174-182.
38. Crommentuyn KM, Kappelhoff BS, Mulder JW, et al. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol. 2005 ; 60: 378-389.
39. Lalonde RL, Ouellet D., Kimanani EK, Potvin D., Vaughan LM, Hill MR Comparison of different methods to evaluate population dose-response and relative potency: importance of interoccasion variability. J Pharmacokinet Biopharm. 1999 ; 27: 67-83.
40. Zhou H. Population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures ? J Clin Pharmacol. 2006 ; 46: 1268-1289.
41. Schmidli H., Peng B., Riviere GJ, et al. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. Br J Clin Pharmacol. 2005 ; 60: 35-44.
42. Lu JF, Eppler SM, Wolf J., et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther. 2006 ; 80: 136-145.
43. Zhou H., Khalilieh S., Lau H., et al. Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919). J Clin Pharmacol. 1999 ; 39: 911-919.
44. Wahlby U., Thomson AH, Milligan PA, Karlsson MO Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis. Br J Clin Pharmacol. 2004 ; 58: 367-377.